

## University of Groningen

### TIME to discuss the optic nerve?

Pappelis, Konstantinos; Apostolos, Anastasios; Konstantinou, Konstantinos; Toutouzas, Konstantinos; Jansonius, Nomdo M.

*Published in:*  
 Eye

*DOI:*  
[10.1038/s41433-023-02555-3](https://doi.org/10.1038/s41433-023-02555-3)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
 Publisher's PDF, also known as Version of record

*Publication date:*  
 2023

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Pappelis, K., Apostolos, A., Konstantinou, K., Toutouzas, K., & Jansonius, N. M. (2023). TIME to discuss the optic nerve? *Eye*, 37, Article 3691. <https://doi.org/10.1038/s41433-023-02555-3>

#### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

#### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## BRIEF COMMUNICATION



## TIME to discuss the optic nerve?

Konstantinos Pappelis<sup>1,2</sup>, Anastasios Apostolos<sup>3</sup>, Konstantinos Konstantinou<sup>3</sup>, Konstantinos Toutouzas<sup>3</sup> and Nomdo M. Jansonius<sup>1,2</sup>

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023

Eye (2023) 37:3691; <https://doi.org/10.1038/s41433-023-02555-3>

The recent large-scale randomized control trial 'Treatment in Morning versus Evening' (TIME) clearly demonstrated that the time of antihypertensive dosing administration does not affect the occurrence of adverse cardiovascular outcomes in patients suffering from arterial hypertension (AHT) [1].

Accumulating evidence implicates nocturnal blood pressure dipping in glaucoma progression, especially in glaucoma patients with normal intraocular pressure [2, 3]. The TIME trial reports no significant difference between evening and morning dosing, with regards to hospitalization due to glaucoma. However, glaucoma is essentially treated in an outpatient setting, i.e., without hospitalization. Even glaucoma surgery is usually performed in an outpatient setting and, if hospitalization is needed, this is often related to comorbidity. Therefore, using hospitalization as a glaucoma proxy could result in underreporting and bias.

Additionally, dipping cannot be easily linked to a dosing time, indicating the need for personalized workup to establish the optimal time for antihypertensive administration. Ophthalmologists have been reluctant to suggest that glaucoma patients with AHT should move their antihypertensive dosing time, for fear of cardiovascular events. Based on the results of the TIME trial, the treating ophthalmologist and cardiologist or internist have more freedom to adjust dosing time for each glaucoma patient, if disease progression asks for a better diurnal blood pressure profile. Importantly, there is room for improvement; even at the level of the general population, recent studies reveal an association between antihypertensive treatment and retinal ganglion cell health [4].

Given that the 2040-projected number of people with glaucoma worldwide exceeds 110 million, and the growing burden related to coexisting glaucoma and AHT is understated in clinical practice, physicians should be alert of patients exhibiting both pathologies [5].

## REFERENCES

1. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. *Lancet*. 2022;400:1417–25.

2. Charlson ME, de Moraes CG, Link A, Wells MT, Harmon G, Peterson J, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. *Ophthalmology*. 2014;121:2004–12.
3. Melgarejo JD, Lee JH, Petitto M, Yépez JB, Murati FA, Jin Z, et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study. *Ophthalmology*. 2018;125:807–14.
4. Pappelis K, Jansonius NM. U-shaped effect of blood pressure on structural OCT metrics and retinal perfusion in ophthalmologically healthy subjects. *Invest Ophthalmol Vis Sci*. 2021;62:5.
5. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121:2081–90.

## AUTHOR CONTRIBUTIONS

KP: conceptualisation, writing. AA: conceptualisation, review & editing. KK: conceptualisation, review & editing. KT: conceptualisation, review & editing. NJ: conceptualisation, supervision, review & editing.

## FUNDING

Supported by Stichting Oogfonds Nederland. The funding organization had no role in the design, conduct, analysis, or publication of this research.

## COMPETING INTERESTS

The author declares no competing interests.

## ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to Konstantinos Pappelis.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

<sup>1</sup>Department of Ophthalmology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. <sup>2</sup>Graduate School of Medical Sciences (Research School of Behavioural and Cognitive Neurosciences), University of Groningen, Groningen, The Netherlands. <sup>3</sup>First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokraton General Hospital, Athens, Greece. ✉email: k.pappelis@rug.nl

Received: 26 March 2023 Revised: 14 April 2023 Accepted: 20 April 2023

Published online: 28 April 2023